Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Clinical trial NCT03710564 · TERMINATED
Trial details
- NCT number
- NCT03710564
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-30
- Primary completion
- 2020-12-21
- Enrollment
- 535
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.